Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab

被引：2
|
作者：
Hiraga, Junji [1 ]
Tomita, Akihiro [2 ]
Suzuki, Naruko [1 ]
Takagi, Yusuke [1 ]
Narita, Michihiko [3 ]
Kagami, Yoshitoyo [1 ]
机构：
[1] Toyota Kosei Hosp, Dept Hematol, 500-1 Ibobara,Josui Cho, Toyota 4700396, Japan
[2] Fujita Hlth Univ, Sch Med, Dept Hematol, Toyoake, Aichi, Japan
[3] Toyota Kosei Hosp, Dept Pathol, Toyota, Japan
来源：
ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 11期
关键词：
CHEMOTHERAPY PLUS RITUXIMAB; CHOP;
D O I：
10.1007/s00277-018-3354-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2253 / 2255
页数：3
相关论文
共 50 条
  • [41] Use of C-terminal deletion mutation of CD20 molecule to predict CD20 expression and time to progression after rituximab in non-Hodgkin lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Mishima, Y.
    Takeuchi, K.
    Ito, Y.
    Takahashi, S.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] THE DIAGNOSTIC CHALLENGE OF RITUXIMAB-INDUCED CD20 NEGATIVE B-CELL LYMPHOMAS
    Risser, J.
    Breen, C.
    Feder, S.
    O'Leary, E.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2011, 38 (01) : 159 - 159
  • [43] CD20 negative posttransplant lymphoproliferative disorder after liver transplantation in complete remission with rituximab
    Rodriguez, Myriam
    Acevedo, Andres
    Castro, Carlos
    Vera, Alonso
    Becerra, Henry
    Felipe Cardona, Andres
    GACETA MEXICANA DE ONCOLOGIA, 2011, 10 (04): : 236 - 244
  • [44] De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity
    Tokunaga, Takashi
    Tomita, Akihiro
    Sugimoto, Keiki
    Shimada, Kazuyuki
    Iriyama, Chisako
    Hirose, Tatsuya
    Shirahata-Adachi, Mizuho
    Suzuki, Yasuhiro
    Mizuno, Hiroki
    Kiyoi, Hitoshi
    Asano, Naoko
    Nakamura, Shigeo
    Kinoshita, Tomohiro
    Naoe, Tomoki
    CANCER SCIENCE, 2014, 105 (01) : 35 - 43
  • [45] Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
    Vockova, P.
    Svaton, M.
    Karolova, J.
    Pokorna, E.
    Vokurka, M.
    Klener, P.
    FOLIA BIOLOGICA, 2020, 66 (01) : 17 - 23
  • [46] PAX5 immunostaining in the diagnosis of relapsed CD20 negative B-cell non Hodgkins lymphomas after treatment with rituximab
    Narbaitz, M. I.
    Kitagawa, R. B.
    Martin, C. A.
    HISTOPATHOLOGY, 2010, 57 : 152 - 152
  • [47] Lw-213 Synergizes with Rituximab to Inhibit Diffuse Large B-Cell Lymphomas By Upregulating CD20
    Li, Yuchen
    Li, Hui
    Hui, Hui
    Xu, Jingyan
    BLOOD, 2021, 138
  • [48] Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report
    Luo, Shuai
    Huang, Xiang
    Li, Yao
    Wang, Jinjing
    BMC NEUROLOGY, 2022, 22 (01)
  • [49] Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
    Xu-Wen Guan
    Hua-Qing Wang
    Wei-Wei Ban
    Zhi Chang
    Hai-Zhu Chen
    Li Jia
    Feng-Ting Liu
    Cell Death & Disease, 11
  • [50] Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
    Guan, Xu-Wen
    Wang, Hua-Qing
    Ban, Wei-Wei
    Chang, Zhi
    Chen, Hai-Zhu
    Jia, Li
    Liu, Feng-Ting
    CELL DEATH & DISEASE, 2020, 11 (01)
12345